New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Your Essential Guide to Navigating IgA Nephropathy

Please fill out this form to receive your free handbook.

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.